Multicenter study for the efficacy of Godex in patients with chronic liver disease and liver cirrhosis

Godex is a mixture of hepadif and biphenyl dimethyl dicarboxylate (DDB), which has hepatoprotective activity. This study evaluated the effect of Godex on biochemical items associated with liver function and hepatitis B virus DNA level to patients with chronic hepatitis, fatty liver and liver cirrhosis. A total of 242 patients with chronic hepatitis, fatty liver and liver cirrhosis who visited to 12 medical centers from Sep. 2002 to Feb. 2005 and have no other medicines except it were enrolled in this study. We retrospectively evaluated the changes of biochemical items such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, albumin, prothrombin time, platelet count and hepatitis B virus DNA level before and at 1, 3, 6, 9 and 12 months after the Godex treatment. In patients with chronic hepatitis, ALT and total bilirubin have shown statistically significant changes (p<0.05). In patients with fatty liver and liver cirrhosis, the ALT level alone was significantly changed (p<0.05). Otherwise, hepatitis B virus DNA level was not changed. Even if some biochemical items were improved in patients with chronic hepatitis, fatty liver and liver cirrhosis after Godex treatment, it did not affect the change of hepatitis B virus DNA level.